ExploRNA Therapeutics is a spin-off from the University of Warsaw, developing next generation mRNA technology for applications such as anti-cancer vaccines.
ExploRNA Therapeutics was founded by Professor Jacek Jemielity, Head of the Bio Organic Chemistry Laboratory at the Center of New Technologies CeNT at the University of Warsaw. Professor Jemielity’s first generation ‘cap modification’ mRNA technology was licensed in 2011 to the German company BioNTech.
According to the company, it’s next generation mRNA (with modified 5′ cap encoding neoantigens) is expected to have significantly improved benefits in stability, translational efficiency, and cost of synthesis.
ExploRNA’s two lead development programs will focus on tumor specific antigen vaccines and the expression of cytokines to promote cytotoxic T cells to eliminate tumor growth.
MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases. Nanobodies® …